A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Trial Profile

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TRIBE
  • Most Recent Events

    • 06 Jun 2017 Results (n=482) of pooled analysis of TRIBE and MOMA studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 24 Mar 2017 Results assessing Autophagy-related polymorphisms as predictor of bevacizumab-mediated toxicity in patients from two randomised trials (TRIBE and FIRE-3; n=657), published in the European Journal of Cancer
    • 11 Oct 2016 Results analysing tandem repeat variation in HIC1 gene predicting outcome for oxaliplatin based chemotherapy from TRIBE and MOMA studies, presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top